An official website of the United States government
Home
Name
Ipilimumab
Alternate Names
Yervoy
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Monoclonal antibody
NSC Number
720801 hybridoma derived
732442 transfectoma derived
Primary Site
Histology
None
Remarks
March 25, 2011: Ipilimumab (Yervoy) is FDA approved ONLY for the treatment of melanoma. Code as treatment when used for melanoma.
4/16/2018 FDA granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.
Ipilimumab is undergoing clinical trials for the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and metastatic hormone-refractory prostate cancer. Until FDA approval is received for treatment for these cancers, code in Other Therapy.
July 28, 2017: Bristol-Myers Squibb Co. said FDA has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.
7/13/2018: FDA has granted accelerated approval to Yervoy (ipilimumab) for use in combination with Opdivo (nivolumab) for the treatment of patients 12 years of age and older with microsatellite in-stability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
March 10, 2020 The FDA granted accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
May 15, 2020: The FDA approved the combination of nivolumab (OPDIVO) plus ipilimumab (YERVOY) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
May 26, 2020: The FDA approved the combination of nivolumab (OPDIVO) plus ipilimumab (YERVOY)and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
4/16/2018 FDA granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.
Ipilimumab is undergoing clinical trials for the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and metastatic hormone-refractory prostate cancer. Until FDA approval is received for treatment for these cancers, code in Other Therapy.
July 28, 2017: Bristol-Myers Squibb Co. said FDA has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.
7/13/2018: FDA has granted accelerated approval to Yervoy (ipilimumab) for use in combination with Opdivo (nivolumab) for the treatment of patients 12 years of age and older with microsatellite in-stability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
March 10, 2020 The FDA granted accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
May 15, 2020: The FDA approved the combination of nivolumab (OPDIVO) plus ipilimumab (YERVOY) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
May 26, 2020: The FDA approved the combination of nivolumab (OPDIVO) plus ipilimumab (YERVOY)and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Coding
This drug should be coded
